drugset / Trial / NCT00513513

TMC114-C227: A Study to Evaluate the Effectiveness and Safety of TMC114 (Darunavir) With a Low Dose of Ritonavir as Monotherapy (no Other Anti-HIV Drugs Will be Given) in Patients Who Have Never Been Treated With Antiretrovirals (Anti-HIV Drugs) Previously

NCT00513513

Phase 2 Terminated 7 enrolled Tibotec Pharmaceuticals, Ireland
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is an open label study (no placebos are used; all patients will receive the true medication) to evaluate the effectiveness of TMC114/rtv in treatment naÃ-ve (never previously received anti-HIV drugs), HIV 1 infected patients.

Timeline

Start
2006-09
Primary completion
2007-09
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Darunavir Small molecule 800 mg Oral
Background Ritonavir Other / unclassified 100 mg Oral